CA2363984A1 - Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation - Google Patents

Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2363984A1
CA2363984A1 CA002363984A CA2363984A CA2363984A1 CA 2363984 A1 CA2363984 A1 CA 2363984A1 CA 002363984 A CA002363984 A CA 002363984A CA 2363984 A CA2363984 A CA 2363984A CA 2363984 A1 CA2363984 A1 CA 2363984A1
Authority
CA
Canada
Prior art keywords
caspase
app
antibody
cleavage
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002363984A
Other languages
English (en)
Inventor
Francois Gervais
Sophie Roy
Donald W. Nicholson
Daigen Xu
George Robertson
Jingqi Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363984A1 publication Critical patent/CA2363984A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La formation du peptide .beta.-amyloïde (A.beta.) et la perte de neurones par apoptose sont des processus intimement liés dans la pathogénèse des maladies neurodégénératives, et notamment la maladie d'Alzheimer. L'invention concerne les rôles des protéases et caspases apoptotiques dans le clivage de la protéine précurseur amyloïde-.beta. (APP) et dans la biogénèse des espèces peptidiques amyloïdogènes A.beta.. L'invention concerne également des anticorps reconnaissant l'APP clivée par une caspase, ainsi que leurs nombreuses utilisations.
CA002363984A 1999-04-15 2000-04-13 Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation Abandoned CA2363984A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12949599P 1999-04-15 1999-04-15
US60/129,495 1999-04-15
PCT/CA2000/000414 WO2000063250A1 (fr) 1999-04-15 2000-04-13 Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2363984A1 true CA2363984A1 (fr) 2000-10-26

Family

ID=22440248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363984A Abandoned CA2363984A1 (fr) 1999-04-15 2000-04-13 Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP1173486A1 (fr)
JP (1) JP2002542261A (fr)
CA (1) CA2363984A1 (fr)
WO (1) WO2000063250A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6162999A (en) 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US20040132049A1 (en) * 2002-06-26 2004-07-08 Bates Paula J. Method for the detection of apoptosis
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2117540A1 (fr) 2007-03-01 2009-11-18 Probiodrug AG Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
EP2334698A1 (fr) * 2008-10-08 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides marqueurs pour déterminer l'occurrence d'un état inflammatoire chez un sujet
EP2376120A2 (fr) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
IT1392238B1 (it) * 2008-12-02 2012-02-22 Fond Santa Lucia Uso della caspasi-3 per la malattia dell'alzheimer
JPWO2010123013A1 (ja) * 2009-04-22 2012-10-25 国立大学法人大阪大学 プロテアーゼ認識配列を有するタグペプチドおよびその利用
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9249231B2 (en) 2010-11-05 2016-02-02 Cell Signaling Technology, Inc. Motif-specific and context-independent antibodies that specifically bind to a cleaved caspase motif
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN111153996B (zh) * 2020-01-10 2021-12-14 苏州睿瀛生物技术有限公司 G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
EP1003543A4 (fr) * 1997-05-19 2001-09-19 Chiron Corp Sequences de gelsoline induisant l'apoptose

Also Published As

Publication number Publication date
EP1173486A1 (fr) 2002-01-23
WO2000063250A1 (fr) 2000-10-26
JP2002542261A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
Gervais et al. Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-β precursor protein and amyloidogenic Aβ peptide formation
CA2363984A1 (fr) Anticorps reconnaissant l'app clivee par les caspases et leurs procedes d'utilisation
Stadelmann et al. Detection of apoptosis in tissue sections
Gervais et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi
US7078191B1 (en) Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
Rohn et al. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain
US5652092A (en) Amyloid precursor proteins and method of using same to assess agents which down-regulate formation of β-amyloid peptide
US7479372B2 (en) Beta-secretase substrates and uses thereof
US5424205A (en) Amyloidin protease and uses thereof
Galvan et al. Caspase cleavage of members of the amyloid precursor family of proteins
US7183070B2 (en) Inhibition of Aβ production by β-secretase BACE2
JP2006149394A (ja) β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US7087399B1 (en) β-secretase and modulation of β-secretase activity
Savage et al. Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the β-amyloid precursor protein
AU679675B2 (en) Methods for detecting beta amyloid precursor protein processing enzymes
Siman et al. Immunolocalization of caspase proteolysis in situ: evidence for widespread caspase-mediated apoptosis of neurons and glia in the postnatal rat brain
Löffler et al. Accumulation of a 50 kDa N-terminal fragment of β-APP695 in Alzheimer's disease hippocampus and neocortex
EP1567647B1 (fr) Substrats notch solubles pour secretase gamma, et procedes et compositions pour l'utilisation de ceux-ci
Sudoh et al. Intracellular site of γ‐secretase cleavage for Aβ42 generation in Neuro 2a cells harbouring a presenilin 1 mutation
US20030211559A1 (en) Preparations of gamma-secretase activity
Lakshmana et al. Amyloid β peptide binds a novel death‐inducing protein, AB‐DIP
Lynham Identification of allosteric inhibitors against caspase-6 activity in Alzheimer's disease
NZ272218A (en) Regulation of formation of beta-amyloid with a beta-amyloid precursor protease inhibitor

Legal Events

Date Code Title Description
FZDE Discontinued